Blue Cross Blue Shield informed us today of their updated policy on Eylea treatment to allow for continued coverage of patients who have lost three lines of vision on an eye chart.
The American Academy of Ophthalmology had urged the insurer to reconsider its Eylea policy and requested a meeting to discuss the dangers of the policy and its impact on patient care.
Today, the insurer met with Academy leaders and explained that the policy was updated. They will be notifying local plans.
Eylea is an effective anti-VEGF treatment for age-related macular degeneration, diabetic retinopathy, and retinal vascular occlusion – potentially blinding eye conditions that affect millions of Americans.
The Academy, a nationwide community of nearly 20,000 medical doctors, thanks Blue Cross Blue Shield for its reconsideration and is satisfied that continued Eylea coverage will allow patients to receive the highest-quality eye care.